Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury

Claim 2

In a process wherein in a mammal, a therapeutic procedure is carried out to reduce or remove a stenosis present within a lumen of a blood vessel, the improvement to prevent restenosis which comprises administering to the mammal a restenosis preventing amount of a compound of formula (I) ##STR2## wherein R 1 is hydroxyl or keto; R 2 is hydrogen, hydroxyl or keto; R 3 is hydroxyl, hydrogen or amino; R 4 and R 5 are hydrogen or amino; with the provisos that when R 3 is hydroxyl both R 4 and R 5 are hydrogen and when R 3 is not hydroxyl, at least one of R 3 , R 4 and R 5 is amino (--NH 2 ) and the other(s) of them are hydrogen or amino, and pharmaceutically acceptable derivatives and salts thereof.

Claim 3

In a process wherein in a mammal, a therapeutic procedure is carried out to reduce or remove a stenosis present within a lumen of a blood vessel, the improvement to reduce the degree of restenosis which comprises administering to the mammal a restenosis reducing amount of a compound of formula (I) ##STR3## wherein R 1 is hydroxyl or keto; R 2 is hydrogen, hydroxyl or keto; R 3 is hydroxyl, hydrogen or amino; R 4 and R 5 are hydrogen or amino; with the provisos that when R 3 is hydroxyl both R 4 and R 5 are hydrogen and when R 3 is not hydroxyl, at least one of R 3 , R 4 and R 5 is amino (--NH 2 ) and the other(s) of them are hydrogen or amino, and pharmaceutically acceptable derivatives and salts thereof.

Claim 4

In a process wherein in a mammal, a therapeutic procedure is carried out to reduce or remove a stenosis present within a lumen of a blood vessel, the improvement to reduce the degree of restenosis which comprises administering to the mammal a restenosis reducing amount of a compound of formula (I) ##STR3## wherein R 1 is hydroxyl or keto; R 2 is hydrogen, hydroxyl or keto; R 3 is hydroxyl, hydrogen or amino; R 4 and R 5 are hydrogen or amino; with the provisos that when R 3 is hydroxyl both R 4 and R 5 are hydrogen and when R 3 is not hydroxyl, at least one of R 3 , R 4 and R 5 is amino (--NH 2 ) and the other(s) of them are hydrogen or amino, and pharmaceutically acceptable derivatives and salts thereof.

Claim 5

The process of claim 1, wherein R 3 is hydroxyl or amino and each of R 4 and R 5 is hydrogen.

Claim 6

The process of claim 2, wherein R 3 is hydroxyl or amino and each of R 4 and R 5 is hydrogen.

Claim 7

The process of claim 1, wherein the compound of formula (I) administered is 27-hydroxycholesterol.

Claim 8

The process of claim 2, wherein the compound of formula (I) administered is 27-hydroxycholesterol.

Claim 9

The process of claim 1, wherein the compound of formula (I) is administered in a pharmaceutically acceptable carrier comprising an aqueous medium containing a pharmaceutically acceptable cyclodextrin in sufficient amount to stabilize the compound of formula (I) in the aqueous medium.

Claim 10

The process of claim 2, wherein the compound of formula (I) is administered in a pharmaceutically acceptable carrier comprising an aqueous medium containing a pharmaceutically acceptable cyclodextrin in sufficient amount to stabilize the compound of formula (I) in the aqueous medium.

Claim 11

The process of claim 1, wherein the therapeutic procedure is a surgical procedure.

Claim 12

The process of claim 2, wherein the therapeutic procedure is a surgical procedure.

Claim 13

The process of claim 1, wherein the therapeutic procedure is balloon, laser or rotameter angioplasty.

Claim 14

The process of claim 2, wherein the therapeutic procedure is balloon, laser or rotameter angioplasty.

Claim 15

The process of claim 1, wherein the therapeutic procedure is balloon angioplasty.

Claim 16

The process of claim 2, wherein the therapeutic procedure is balloon angioplasty.

Claim 17

The process of claim 1, wherein the compound of claim 1 is administered in an amount of about 10 to 100 mg/kg 1 to 3 times a day.

Claim 18

The process of claim 2, wherein the compound of claim 1 is administered in an amount of about 10 to 100 mg/kg 1 to 3 times a day.

Claim 19

The process of claim 1, wherein the compound of formula (I) is administered as the compound itself or as a mono- or di-ester, or mono- or di-ether thereof.

Claim 20

The process of claim 2, wherein the compound of formula (I) is administered as the compound itself or as a mono- or di-ester, or mono- or di-ether thereof.

Claim 21

The process of claim 1 wherein the compound of formula (I) is administered prior to, during and/or after the therapeutic procedure.

Claim 22

The process of claim 2 wherein the compound of formula (I) is administered prior to, during and/or after the therapeutic procedure.

Claim 23

The process of claim 1 wherein the compound of formula (I) is administered after the therapeutic procedure.

Claim 24

The process of claim 2 wherein the compound of formula (I) is administered after the therapeutic procedure.

Claim 25

In a process wherein in a mammal, a therapeutic procedure is carried out to reduce or remove a stenosis present within a lumen of a blood vessel, the improvement to reduce the degree of restenosis which comprises administering to the mammal a sterol 27-hydroxylase stimulant in an amount sufficient for reducing said degree of restenosis.

Claim 26

In a process wherein in a mammal, a therapeutic procedure is carried out to reduce or remove a stenosis present within a lumen of a blood vessel, the improvement to reduce the degree of restenosis which comprises administering to the mammal a sterol 27-hydroxylase stimulant in an amount sufficient for reducing said degree of restenosis.

Claim 27

In a process wherein in a mammal, a therapeutic procedure is carried out to reduce or remove a stenosis present within a lumen of a blood vessel, the improvement to prevent restenosis which comprises administering to the mammal a sterol 27-hydroxylase stimulant in an amount sufficient for preventing restenosis.

Claim 28

In a process wherein in a mammal, a therapeutic procedure is carried out to reduce or remove a stenosis present within a lumen of a blood vessel, the improvement to prevent restenosis which comprises administering to the mammal a sterol 27-hydroxylase stimulant in an amount sufficient for preventing restenosis.